Drug
Zoledronic Acid
Zoledronic Acid: highest development phase Post-Market, developed by Novartis. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| zoledronic acid NCT00099541 | Post-Market | Non-Small-Cell Lung Cancer |
| Zoledronic acid NCT00966992 | Phase 2 | Uterine Cervical Neoplasms |
| zoledronic acid NCT00264420 | Phase 1 | Bone Metastases |
Latest
No recent events.
Follow Zoledronic Acid on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.